JHOP - September 2019 Vol 9, No 3
Comparing Granulocyte Colony-Stimulating Factors Prescribing Practices versus Guideline Recommendations in a Large Community Cancer Center
Kirollos S. Hanna, PharmD, BCPS, BCOP, Robert Mancini, PharmD, BCOP, Dave Wilson, PharmD, Dan Zuckerman, MD
Neutropenia is a common dose-limiting toxicity of myelosuppressive chemotherapy and exposes patients to life-threatening infections and treatment delays. Febrile neutropenia, a concerning complication of chemotherapy, is defined as neutropenia associated with an oral temperature of more than 38.5°C or 2 consecutive readings of more than 38.0°C for 2 hours and an absolute neutrophil count of <0.5 × 109/L, or a count that is expected to decrease to less than 0.5 × 109/L within 48 hours.
Thromboprophylaxis in Patients with Newly Diagnosed Multiple Myeloma Who Received Lenalidomide-Based Regimens
Serena Chew, PharmD, BCOP, Salma Afifi, PharmD, BCOP, Michelle Nadeau Nguyen, PharmD, BCPS, Man-Yee Merl, PharmD, BCOP
Venous thromboembolism (VTE) is a major complication of hematologic malignancies and is associated with significant morbidity and mortality. Patients with multiple myeloma are especially at risk for VTEs based on the underlying disease pathophysiology and the treatments used for this patient population, specifically immunomodulatory drugs (IMiDs). The risk for VTE among patients ranges from 26% to 67% for those with newly diagnosed multiple myeloma, and from 11% to 15% for patients with relapsed or refractory multiple myeloma. The use of IMiDs further increases the risk for thromboembolic complications, particularly within the first 6 months of therapy, although this risk decreases over time.
We read with great interest the article by Al-Jammali and colleagues (June 2019 issue), which discussed the challenges associated with the use of anticoagulants for patients who have atrial fibrillation after starting treatment with ibrutinib. We believe that this topic is very timely, given the widespread use of ibrutinib in clinical practice; however, we would like to raise some concerns.
Review of Biosimilars and Their Potential Use in Oncology Treatment and Supportive Care in the United States
Biologic drugs play an important role in healthcare and represent $232 billion in global revenue. Biologic drugs represent 25% of the total global pharmaceutical market. The number of biologic drugs approved by the US Food and Drug Administration (FDA) continues to increase, with 12 biologic drugs included in the 46 new molecular entities approved by the FDA in 2017. In addition, 10 new biologics were approved by the FDA in 2018, 40% of which were for the treatment of cancer. Biologic drugs are an important therapeutic option for patients with cancer and are used for the treatment of malignancies as well as for supportive care management.
Targeting FLT3 and KIT Mutations in AML with Midostaurin: Implications for Clinicians and Pharmacists
Many approaches for improving outcomes in patients with acute myeloid leukemia (AML) have been investigated over the years. AML is molecularly complex, and its multiple genetic aberrations are critical pathophysiologic and prognostic features that can influence therapy. Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, identified in approximately 30% of adults with AML, likely confer the largest single-gene impact on overall survival; the FLT3 internal tandem duplication (ITD) mutation is an independent predictor of a high relapse rate and poor overall survival.
The page numbers in the June 2019 issue were incorrectly numbered 1 through 52. The correct numbers in that issue should have been 57-108. This is now corrected in the current issue, and the articles carry the correct continuing page numbers, disregarding the error in the June issue.
Results 1 - 6 of 6